![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BANYU PHARMACEUTICAL ANNOUNCES SUBANALYSIS OF J-LIT, LARGE-SCALE CLINICAL TRIALS OF ANTI-HYPERLIPIDEMIC AGENT LIPOVAS
BANYU PHARMACEUTICAL ANNOUNCES SUBANALYSIS OF J-LIT, LARGE-SCALE CLINICAL TRIALS OF ANTI-HYPERLIPIDEMIC AGENT LIPOVAS
Banyu Pharmaceutical recently published the results of the Japan Lipid Intervention Trial (J-LIT), large-scale clinical trials of LIPOVAS, its proprietary anti-hyperlipidemic agent, in Circulation Journal, an academic and professional publication of the Japanese Circulation Society.
JCN Network (http://www.japancorp.net/Article.Asp?Art_ID=12768)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct